September 22nd 2025
Off-the-shelf mosunetuzumab/polatuzumab vedotin produced durable responses with manageable safety in BTK inhibitor–exposed relapsed/refractory MCL.
FDA Approves Acalabrutinib-Based Regimen for Previously Treated MCL
Published: January 16th 2025 | Updated: January 17th 2025The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous stem cell transplant.
Autologous HCT Does Not Provide Added Survival Benefit in Patients With MCL in First CR
December 10th 2024Patients with mantle cell lymphoma in first complete response with undetectable MRD did not benefit from consolidative autologous transplant, according to results from the ECOG-ACRIN EA4151/BMT-CTN 1601 trial.